Skip to main content

Table 1 The favorable and unfavorable outcome groups among 123 patients with purely ocular myasthenia

From: Quality of life in purely ocular myasthenia in Japan

 

Favorable outcome

Unfavorable outcome

 
 

(n = 76)

(n = 47)

p-value

Female

42 (55%)

27 (57%)

0.81

Age, yr

61.1 ± 16.1

60.4 ± 15.4

0.81

Observational period, yr

7.2 ± 4.6

8.7 ± 7.7

0.22

Subtype

   

Early-onset

23 (30%)

18 (38%)

0.33

Late-onset

42 (55%)

26 (55%)

1.00

Thymoma-associated

11 (14%)

3 (6%)

0.17

Symptoms

   

Ptosis and diplopia

49 (64%)

32 (68%)

0.68

Ptosis alone

22 (29%)

14 (30%)

0.92

Diplopia alone

5 (7%)

1 (2%)

0.26

Anti-acetylcholine receptor positive

60 (79%)

32 (68%)

0.18

Treatment

   

Acetyl-cholinesterase inhibitors

58 (86%)

41 (78%)

0.14

Pyridostigmine (mg/day)

79.7 ± 66.6

132.0 ± 54.0

<0.0001

Oral prednisolone

27 (36%)

25 (53%)

0.053

Maximum dose (mg/day)

19.4 ± 10.4

21.5 ± 15.5

0.58

Immunosuppressants

14 (18%)

14 (30%)

0.14

mPSL

11 (14%)

12 (26%)

0.13

Plasmapheresis

2 (3%)

4 (9%)

0.14

Immunoglobulin

1 (1%)

0 (0%)

0.43

Thymectomy

20 (26%)

11 (23%)

0.71

Ocular-QMG score

   

Pre-treatment

3.4 ± 1.7

4.5 ± 1.7

0.006

Post-treatment

0.6 ± 0.8

3.4 ± 2.1

<0.0001

MG-QOL15-J score

5.7 ± 8.5

15.7 ± 12.7

<0.0001

  1. mPSL, intravenous methylpredonisolone pulse therapy.
  2. QMG, quantitative MG score; MGFA, Myasthenia Gravis Foundation of America.